Market research
HBP.F Helix BioPharma Corp
F EUR Not available
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 78M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -0.67
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 78M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -0.67
About
About Helix BioPharma Corp
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
Research context
Helix BioPharma Corp appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the HBP.F discussion.
5 years, 7 months ago
Helix BioPharma Corp is currently in a long term uptrend where the price is trading 36.6% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Helix BioPharma Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 11.7% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 37.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Helix BioPharma Corp gets an overall score of 2/5.